Skip to main content
SpringerLink
Log in

Intranasal Treatment in Subarachnoid Hemorrhage

  • Chapter
  • First Online:
Therapeutic Intranasal Delivery for Stroke and Neurological Disorders

Part of the book series: Springer Series in Translational Stroke Research ((SSTSR))

  • 343 Accesses

Abstract

Aneurysmal subarachnoid hemorrhage is a devastating disease because of the initial mortality rate and delayed cerebral iscemia which can be caused by several pathological mechanisms not fully understood yet. To date there is no specific treatment for the delayed cerebral iscemia. One of the most important challenges in subarachnoid hemorrhage research area is the blood brain barrier. Intranasal treatment is a promising way of treatment to bypass the blood brain barrier. In this chapter intranasal treatment options in subarachnoid hemorrhage will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Topkoru B, Egemen E, Solaroglu I, Zhang JH. Early brain injury or vasospasm? An overview of common mechanisms. Curr Drug Targets. 2017;18(12):1424–9.

    Article  CAS  Google Scholar 

  2. Caner B, Hou J, Altay O, Fuj M 2nd, Zhang JH. Transition of research focus from vasospasm to early brain injury after subarachnoid hemorrhage. J Neurochem. 2012;123(Suppl 2):12–21.

    Article  CAS  Google Scholar 

  3. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, Hoh BL, Kirkness CJ, Naidech AM, Ogilvy CS, Patel AB, Thompson BG, Vespa P, American Heart Association Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia, Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711–37.

    Article  Google Scholar 

  4. Grasso G, Tomasello F. Erythropoietin for subarachnoid hemorrhage: is there a reason for hope. World Neurosurg. 2012;77(1):46–8.

    Article  Google Scholar 

  5. Chapman CD, Frey WH 2nd, Craft S, Danielyan L, Hallschmid M, Schiöth HB, Benedict C. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013;30(10):2475–84.

    Article  CAS  Google Scholar 

  6. Patel MM, Patel BM. Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31:109–33.

    Article  CAS  Google Scholar 

  7. Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014;5(6):709–33.

    Article  CAS  Google Scholar 

  8. Thorne RG, Emory CR, Ala TA, Frey WH 2nd. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995;692:278–82.

    Article  CAS  Google Scholar 

  9. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99:1654–73.

    Article  CAS  Google Scholar 

  10. Suzuki H, Hasegawa Y, Chen W, Kanamaru K, Zhang JH. Recombinant osteopontin in cerebral vasospasm after subarachnoid hemorrhage. Ann Neurol. 2010;68:650–60.

    Article  CAS  Google Scholar 

  11. Topkoru BC, Altay O, Duris K, Krafft PR, Yan J, Zhang JH. Nasal administration of recombinant osteopontin attenuates early brain injury after subarachnoid hemorrhage. Stroke. 2013;44(11):3189–94.

    Article  CAS  Google Scholar 

  12. Doyle KP, Yang T, Lessov NS, Ciesielski TM, Stevens SL, Simon RP, et al. Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab. 2008;28:1235–48.

    Article  CAS  Google Scholar 

  13. Zhang JH. Vascular neural network in subarachnoid hemorrhage. Transl Stroke Res. 2014;5(4):423–8.

    Article  Google Scholar 

  14. Wu J, Zhang Y, Yang P, Enkhjargal B, Manaenko A, Tang J, Pearce WJ, Hartman R, Obenaus A, Chen G, Zhang JH. Recombinant osteopontin stabilizes smooth muscle cell phenotype via integrin receptor/integrin-linked kinase/Rac-1 pathway after subarachnoid hemorrhage in rats. Stroke. 2016;47(5):1319–27.

    Article  CAS  Google Scholar 

  15. Lau WL, Leaf EM, Hu MC, et al. Vitamin d receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012;82:1261–70.

    Article  CAS  Google Scholar 

  16. Enkhjargal B, McBride DW, Manaenko A, Reis C, Sakai Y, Tang J, Zhang JH. Intranasal administration of vitamin D attenuates blood-brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats. J Cereb Blood Flow Metab. 2017;37(7):2555–66.

    Article  CAS  Google Scholar 

  17. Xie Z, Huang L, Enkhjargal B, Reis C, Wan W, Tang J, Cheng Y, Zhang JH. Intranasal administration of recombinant Netrin-1 attenuates neuronal apoptosis by activating DCC/APPL-1/AKT signaling pathway after subarachnoid hemorrhage in rats. Neuropharmacology. 2017;119:123–33.

    Article  CAS  Google Scholar 

  18. Donega V, Nijboer CH, Braccioli L, Slaper-Cortenbach I, Kavelaars A, van Bel F, Heijnen CJ. Intranasal administration of human MSC for ischemic brain injury in the mouse: in vitro and in vivo neuroregenerative functions. PLoS One. 2014;9(11):e112339.

    Article  Google Scholar 

  19. Onda T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. J Cereb Blood Flow Metab. 2008;28(2):329–40.

    Article  CAS  Google Scholar 

  20. Khalili MA, Anvari M, Hekmati-Moghadam SH, Sadeghian-Nodoushan F, Fesahat F, Miresmaeili SM. Therapeutic benefit of intravenous transplantation of mesenchymal stem cells after experimental subarachnoid hemorrhage in rats. J Stroke Cerebrovasc Dis. 2012;21:445–51.

    Article  Google Scholar 

  21. Khalili MA, Sadeghian-Nodoushan F, Fesahat F, Mir-Esmaeili SM, Anvari M, Hekmati-Moghadam SH. Mesenchymal stem cells improved the ultrastructural morphology of cerebral tissues after subarachnoid hemorrhage in rats. Exp Neurobiol. 2014;23:77–85.

    Article  Google Scholar 

  22. Nijboer CH, Kooijman E, van Velthoven CT, van Tilborg E, Tiebosch IA, Eijkelkamp N, Dijkhuizen RM, Kesecioglu J, Heijnen CJ. Intranasal stem cell treatment as a novel therapy for subarachnoid hemorrhage. Stem Cells Dev. 2018;27(5):313–25.

    Article  CAS  Google Scholar 

  23. Rashed HM, Shamma RN, Basalious EB. Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery. Drug Deliv. 2016;24(1):181–7.

    Article  Google Scholar 

  24. Garcia-Rodiriguez JC, Sosa-Teste I. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. Sci World J. 2009;9:970–81.

    Article  Google Scholar 

  25. Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir. 2007;149:1089–101.

    Article  CAS  Google Scholar 

  26. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg. 2009;111:171–80.

    Article  CAS  Google Scholar 

  27. Muñoz-Cernada A, Pardo-Ruiz Z, Montero-Alejo V, Fernández-Cervera M, Sosa-Testé I, García-Rodríguez JC. Effect of nonionic surfactants and HPMC F4M on the development of formulations of Neuro-EPO as a neuroprotective agent. JAPST. 2014;1:22–35.

    Article  Google Scholar 

  28. Santos-Morales O, Díaz-Machado A, Jiménez-Rodríguez D, Pomares-Iturralde Y, Festary-Casanovas T, González-Delgado CA, Pérez-Rodríguez S, Alfonso-Muñoz E, Viada-González C, Piedra-Sierra P, García-García I, Amaro-González D, NeuroEPO Study Group. Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study. BMC Neurol. 2017;17(1):129. https://doi.org/10.1186/s12883-017-0908-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Grinberg YY, Zitzow LA, Kraig RP. Intranasally administered IGF-1 inhibits spreading depression in vivo. Brain Res. 2017;15(1677):47–57.

    Article  Google Scholar 

  30. Zhuang Z, Zhao X, Wu Y, Huang R, Zhu L, Zhang Y, Shi J. The anti-apoptotic effect of PI3K-Akt signaling pathway after subarachnoid hemorrhage in rats. Ann Clin Lab Sci. 2011;41(4):364–72.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Medeniyet University Goztepe Education and Research Hospital, Istanbul, Turkey

    Basak Caner

Authors
  1. Basak Caner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA

    Jun Chen

  2. Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Jian Wang

  3. Departments of Anesthesiology and Neurology, Emory University School of Medicine, Atlanta, GA, USA

    Ling Wei

  4. Department of Physiology, Loma Linda University School of Medicine, Loma Linda, CA, USA

    John H. Zhang

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Caner, B. (2019). Intranasal Treatment in Subarachnoid Hemorrhage. In: Chen, J., Wang, J., Wei, L., Zhang, J. (eds) Therapeutic Intranasal Delivery for Stroke and Neurological Disorders. Springer Series in Translational Stroke Research. Springer, Cham. https://doi.org/10.1007/978-3-030-16715-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16715-8_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16713-4

  • Online ISBN: 978-3-030-16715-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation